-
Current clinical trial evidence favors the use of aspirin or clopidogrel as first-line agents for the majority of patients with vascular disease.
-
The Medical Letter describes rifaximin as one alternative to a quinolone antibiotic for treatment of travelers diarrhea, while noting that for severe diarrhea a fluoroquinolone is preferred.
-
The first head-to-head comparison study of an ACE inhibitor and an angiotensin receptor blocker, to assess renoprotective effects in type 2 diabetes, has shown that the drugs are comparable in their benefit.
-
SOS, in part, can be attributed to PD-specific pathology because disease duration and subjective disease severity have been shown to be predictors of SOS.
-
The severity of the neuropathy and the availability of potential treatments, including avoidance of provocative factors, make identification important.
-
These results demonstrate a major role of carotid thrombosis and inflammation in ischemic stroke in patients affected by carotid atherosclerotic disease.
-
The mortality associated with bacterial meningitis remains high, and the strongest risk factors for an unfavorable outcome are those that are indicative of systemic compromise, a low level of consciousness, and infection with S. pneumoniae.
-
-
A recent study suggests that 250 mg doses of acetazolamide might be more effective than 125 mg doses in combating acute mountain sickness. Nonetheless, the applicability of these findings to travelers reaching high altitudes remains unclear.
-
Death occurred in about 1 per 100 cases of malaria diagnosed in U.S. travelers from 1963 to 2001, and many factors contribute to death from malaria. Most were preventable, and people returning home to visit friends and relatives have now become the leading risk group for malaria-related deaths.
